Senetek acquires rights to additional anti-cancer RNAi technology

Published: 19-Dec-2008
Sustainability Research & Development

Senetek, a US life sciences company that develops technologies targeting the science of healthy aging, has signed an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poland for the exclusive rights to a new tumour treatment using an RNAi-based therapeutic technology for use against a broad range of cancers.


Senetek, a US life sciences company that develops technologies targeting the science of healthy aging, has signed an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poland for the exclusive rights to a new tumour treatment using an RNAi-based therapeutic technology for use against a broad range of cancers.

This technology, which targets a cancer biomarker, was developed by the Institute with the Department of Neurosurgery and Neurotraumatology at the University of Medical Sciences in Poznań. Under the terms of the agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid on commercialisation.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
  2. New NICE thresholds: good news for rare disease drugs but process remains complex Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
  3. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
  4. Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
  5. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Subscribe now